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Background: APOAI, a member of the APOAI/CIII/IV/V gene cluster on chromosome 11q23-24, encodes a major
protein component of HDL that has been associated with serum lipid levels. The aim of this study was to
determine the genetic association of polymorphisms in the APOAI promoter region with plasma lipid levels in a
cohort of healthy Kuwaiti volunteers.
Methods: A 435 bp region of the APOAI promoter was analyzed by re-sequencing in 549 Kuwaiti samples.
DNA was extracted from blood taken from 549 healthy Kuwaiti volunteers who had fasted for the previous 12 h.
Univariate and multivariate analysis was used to determine allele association with serum lipid levels.
Results: The target sequence included a partial segment of the promoter region, 5’UTR and exon 1 located
between nucleotides −141 to +294 upstream of the APOAI gene on chromosome 11. No novel single nucleotide
polymorphisms (SNPs) were observed. The sequences obtained were deposited with the NCBI GenBank with
accession number [GenBank: JX438706]. The allelic frequencies for the three SNPs were as follows: APOAI
rs670G = 0.807; rs5069C = 0.964; rs1799837G = 0.997 and found to be in HWE. A significant association (p < 0.05)
was observed for the APOAI rs670 polymorphism with increased serum LDL-C. Multivariate analysis showed that
APOAI rs670 was an independent predictive factor when controlling for age, sex and BMI for both LDL-C
(OR: 1.66, p = 0.014) and TC (OR: 1.77, p = 0.006) levels.
Conclusion: This study is the first to report sequence analysis of the APOAI promoter in an Arab population.
The unexpected positive association found between the APOAI rs670 polymorphism and increased levels of
LDL-C and TC may be due to linkage disequilibrium with other polymorphisms in candidate and neighboring
genes known to be associated with lipid metabolism and transport.
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Plasma lipids have an essential role in several metabolic
systems including the endocrine, nervous and circulatory
systems [1] and their levels are influenced by lifestyle
factors such as diet, physical activity and smoking, as
well as genetic factors [2,3]. Variation in plasma lipid
levels, commonly referred to as dyslipidemia, is charac-
terized by increased total cholesterol (TC), triglycerides
(TG), and low-density lipoprotein (LDL) as well as
decreased high-density-lipoprotein (HDL). Dyslipiemia
is commonly present among people whose diet is high
in fat and low in fiber [4]. Twin and family studies have
shown that plasma lipid levels are particularly influenced
by genetic factors with a widely reported variation of
heritability ranging from 40-60% [2]. Since lipid levels
may be under genetic control [2,5], the identification
and characterization of genetic variants associated with
plasma concentrations may provide some insight into
the genotype-phenotype relationship [3] and allow for
lifestyle adjustments to improve health. Several reports,
including the Genome Wide Association Studies, have
attempted to elucidate the genetic and molecular mecha-
nisms of dyslipidemia based on measurements of plasma
lipids and have identified a limited number of candidate
genes and pathways relevant to lipid metabolism and/or
transport [3,6-11].
The APOAI gene encodes a major protein component
of HDL that forms a structural part of the lipoprotein
particles with a primary function in signaling and tar-
geting lipoproteins in the reverse cholesterol transport
from peripheral tissues to the liver for its excretion. It is
also an important cofactor for lecithin cholesterolacyl-
transferase (LCAT) which catalyzes the formation of
plasma cholesterol esters in the plasma [12] for their
transfer from peripheral tissues. The gene encodes a
267 amino acid polypeptide, synthesized in the liver
and intestine, where it undergoes intracellular cleavage
followed by extracellular proteolysis yielding the mature
243 amino acid apoA-I polypeptide [13]. The APOAI
gene is part of the APOAI/CIII/IV/V gene cluster located
in chromosome 11q23-24 spanning over 20 Kb [14].
This gene cluster has been shown to have a relationship
to dyslipidemia with different polymorphisms in each
gene having varying degrees of association with different
plasma lipids. There is much controversy regarding the
association of specific reported single nucleotide poly-
morphisms (SNPs) at the APOAI locus with dyslipidemia.
Several SNPs have been documented that are reported
to be associated to HDL and cholesterol levels, including
g.-75G >A (rs670), g. + 83C > T (rs5069) and g. + 84G >A
(rs1799837). The rs670 variation has been reported to
enhance promoter function [15] with the minor allele (A)
being associated with abnormal variation in lipid levels in
several populations [11,16-21]. In contrast, studies havereported this variant having decreased promoter activity
[22], while others showed no effect on promoter activity
[23]. In addition, several studies have reported different
mutations in the coding region of the gene to be associ-
ated with reduced levels of HDL-C [8,13,24-27]. Another
variation slightly further downstream is a C to a T transi-
tion at position rs5069 which occurs simultaneously or
independently of a second transition from a G to an A
at position rs1799837 [15,17,19,28,29]. The minor allele
T for rs5069 is associated with increased HDL-C
[15-17,19,29,30] and decreased TG levels [18] while the
minor allele A for rs1799837 appears to be associated with
HDL-C levels [15,27] as well as with heart disease [27].
The exact polymorphisms responsible for the apparent
influence of this locus on HDL levels in particular are
not fully elucidated [31] and very few studies have
found an association with other lipid levels. It is well
established that differences among populations in the
relative frequency of ‘susceptibility genotypes’ or environ-
mental exposure may contribute to the utility of a geno-
type for predicting a trait within a particular population
[32,33]. These kinds of genetic association studies with
regards to APOAI have not been investigated in the
Kuwaiti population and there are only limited reports
on other Arab populations [34,35]. Traditionally, the
Kuwaiti/Arab diet is high in fat, raising the risk factors
of cardiovascular diseases such as diabetes mellitus,
dyslipidemia, obesity and hypertension. Studies on the
lipid profiles of the Kuwaiti population [36] have reported
a higher prevalence of hypercholesterolemia in women
(36.6%) than in men (30.2%) with hypertriglyceridemia
being higher in men (44.1%) than in women (33.8%)
The Kuwaiti population also ranks high worldwide in
prevalence of overweight (80.4%), obesity (47.5%), and
metabolic syndrome (36.2%) [37]. It is hypothesized
that the reported high frequencies of dyslipidemia and
their association to metabolic syndrome are the outcome
of an interaction between established risk factors and
genetic polymorphisms. The objective of the present
study was to assess the association of several genetic
polymorphisms in the promoter region of the APOAI
gene locus found by re-sequencing, with variation in




This study was undertaken within the guidelines set
by the Declaration of Helsinki and was reviewed and
approved by the Local Ethical Committee at Kuwait
University. The cohort in this study (n = 549) included
213 male and 336 female ethnic Kuwaiti nationals with
ages ranging from 18 to 72 y with a mean of 29 y (±0.54
SEM). Whole blood was collected, with informed consent,
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regional polyclinic or at one of the major hospitals in
Kuwait. The randomized sample included 154 individuals
with increased levels of serum TC (>5.17 mmol/L), 11 with
increased TG levels (>2.19 mmol/L), 85 with increased
levels of LDL-C (>3.2 mmol/L) and 113 with abnormal
HDL-C levels (≤1.3 mmol/L). For each individual, several
phenotypic variables including BMI (Table 1) and family
history of hypercholesterolemia, hypertension, diabetes
and heart disease were recorded.
Biochemical analysis and diagnostic criteria
A venous blood sample of 11 ml was obtained from all
individuals who had previously fasted for at least 12 h.
About 3 ml was used to determine serum lipid levels
and 5 ml were transferred to tubes with anti-coagulant
and used to extract genomic DNA. The levels of serum
TC, TG, HDL-C, and LDL-C in each sample were deter-
mined by enzymatic methods with commercially avail-
able kits and performed on a UniCel DxC 800 Synchron
Clinical System from Beckman Coulter (USA) in the
Clinical Chemistry facility at Al-Amiri Hospital. Individ-
uals were considered normal if their serum values for TC,
TG, HDL-C and LDL-C fell within the Kuwaiti popula-
tion reference range of 3.0–5.17, 0.40–2.19, 0.91–1.3
and 1.8–3.2 mmol/L, respectively. The cohort was divided
into two groups normal and abnormal by each lipid par-
ameter. Normal weight, overweight and obesity were de-
fined as a BMI < 24, 24–28, and > 28 kg/m2, respectively.
Re-sequencing of the partial region in the promoter/exon
1 of the APOAI gene locus
A 435 bp region of the APOAI promoter was analyzed
by direct sequencing in 549 Kuwaiti samples. Genomic
DNA was extracted from 5ml of whole blood using a
proteinase K digestion and salting out extraction method
as previously described by Miller et al. [38]. The purified
DNA samples were first subjected to PCR amplificationTable 1 Demographic and clinical features of
study cohort
Parameters
Sex (Males, Females) 38.8%, 61.2%
Age (yr) 29 ± 0.54
BMI 27 ± 0.29
Cholesterol (mmol/L) 4.6 ± 0.03
LDL (mmol/L) 3.05 ± 0.03
HDL (mmol/L) 1.18 ± 0.01
Triglyceride (mmol/L) 0.92 ± 0.03
Positive family history of hypercholesterolemia 32.42%
Positive family history of heart disease 33.88%
Data shown as means ± SEM or for the BMI and lipid levels except for TG
where the median and inter-quartile range is represented.of the target sequence in the promoter region with the
following primers: (forward) 5′-AGGGACAGAGCTGA
TCCTTGAACTCTT AAG −3′ and (reverse) 5′-TTAGG
GGACACCTAC CCGTCAGGAAGAGCA-3′ using Fast
Amplitaq Gold PCR Master Mix 1.25 ml in an Applied
Biosystems Fast thermal cycler (Version 1.01, Life Tech-
nologies). An initial denaturation step of 95°C for 10 sec
was followed by 35 cycles of denaturation at 94°C for
10 sec, 55°C for 25 sec, a final extension of 72°C for 30 sec
and a subsequent hold at 4°C. The amplified PCR products
(10 μl) were then purified with a Nucleospin column followed
by formaldehyde denaturation. Sequencing was performed
twice in two separate reactions, one with the forward
primer and the other with the reverse primer for all
samples in Fast thermal cycler (Life Technologies, Applied
Biosystems) with an initial denaturation of 96°C for 1 min
followed by 25 cycles of denaturation at 96°C for 10 sec,
50°C for 5 sec and 60°C for 1.15 min and a hold at 4°C.
The sequence extension products were then mixed with
Xterminator solution (10ul) and Sam solution (45 ul)
from the Big Dye Xterminator purification kit (Life
Technologies, Applied Biosystems) and analyzed by
capillary electrophoresis on the ABI Gene Analyzer
3130xl (Life Technologies, Applied Biosystems). The
sequence data was documented on electropherogram files
and subjected to analysis by the data collection software
package (Version 3.0).
The sequences from the two reactions were compared
for quality assurance and aligned by ClustalW (Multiple
Alignment Tool) to screen for all novel and/or mutations.
Multiple sequence alignment among all samples and in
comparison to the reference sequence revealed only three
APOAI polymorphisms (rs670, rs5069 and rs1799837) out
of the 11 reported variants in the Genbank databases.
(http://www.ncbi.nlm.nih.gov/gene).
The genotypes of the APOAI rs670, rs5069 and rs17
99837 were also determined by sequence alignment with
the published sequences [NCBI RefSeq: NT_033899.8]
in the Genbank database for the promoter region of the
APOAI employing BLAST sequence analysis (http://www.
ncbi.nlm.nih.gov/gene).
Statistical analysis of the association between the APOAI
SNP’s and serum lipid levels
The allele and genotype frequencies were determined by
simple gene-counting method for the polymorphisms
including the APOAI rs670, rs5069 and rs1799837 and
correlated with the individual phenotypic variables includ-
ing serum lipid levels and documented family history of
various complex diseases expressed as mean ± SEM, me-
dian, interquartile range and percentage where appropriate
(Table 1). Hardy-Weinberg equilibrium (HWE) was tested
using the GENEPOP [39] software (Version 4.0.10) with
significance at p < 0.05. The relation between APOAI
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Wallis ANOVA and the Mann–Whitney U tests where
appropriate and multiple linear regression, using SPSS
(version 19.0). A two-tailed p < 0.05 was considered as
statistically significant. Multivariate analysis using logistic
regression was used to identify the predictor factors
expressed by odds ratio (OR) with 95% confidence inter-
vals using R software environment (R Version 2.7.1) [40].
To estimate the power of the study, the sample size of 549
was analyzed using the Power and Sample Calculation
Program (version 3.0.43) [41].
Results
Sequence analysis and molecular screening
The 435 nucleotide sequence which included a partial
segment of the APOAI promoter region, 5’UTR, intron
and exon 1 located between nucleotides −141 to +294
upstream of the human APOAI gene at contig nucleo-
tide position 20270896 – 20270462 of chromosome 11
(Figure 1) was analyzed for all 549 samples and alignedFigure 1 An electropherogram of the 435 bp sequence data for the p
reverse primer. The peaks represent the various nucleotides detected wh
the quality assurance (95%) of the base call. The SNPs genotyped are indic
red and yellow box shown above the arrow had quality assurance <95% a
sequence alignment with the sequence generated by the forward primer.
GA for rs670, CT for rs5069 and homozygote GG for rs1799837. This sequen
(http://www.ncbi.nlm.nih.gov/Genbank) with accession number [JX438706]with the reference sequence to genotype the three SNP’s
and to screen for putative polymorphisms. No novel SNP’s
were observed; the sequences obtained were deposited
in the NCBI Genbank with accession number [GenBank:
JX438706]. The most common genotypes observed for
the APOAI rs670, rs5.69, rs1799837 polymorphisms were
those for the homozygote wildtype allele (Table 2). The
least common genotype for the rs670 polymorphism was
homozygote AA (3.8%) for the minor allele. Only one indi-
vidual was observed with the homozygote TT for rs5069
while only three heterozygotes were observed for the
rare allele rs1799837 and no homozygotes were identified.
The allelic frequencies for all three SNP’s were as follows:
APOAI rs670G = 0.807; rs5069C = 0.964; rs1799837G =
0.997. The genotype and allele frequencies at all three loci
were found to be in HWE.
Association between the APOAI SNP’s and serum lipid levels
The relationship between genotype frequencies and serum
levels of TC, TG, LDL-C and HDL-C are presented inromoter region at the APOAI gene locus generated by the
ich are discriminated by the fluorescent color. The blue box on top is
ated with and an arrow at positions −75, +83, +84 on the figure. The
s a result of heterozygosity at those positions and was confirmed by
The Kuwaiti individual in the figure was genotyped as a heterozygote
ce has been deposited along with the other 548 in the NCBI Genbank
.
Table 2 Genotype and allele frequencies of the APOAI
promoter region polymorphisms
SNP Genotype n % Allele Allele frequency
APOA1 rs670bp
GG 358 65.20
GA 170 31.00 G 0.807
AA 21 3.80 A 0.193
APOA1 rs5069
CC 511 93.10
CT 37 6.70 C 0.964
TT 1 0.20 T 0.360
APOA1 rs1799837
GG 546 99.45
GA 3 0.55 G 0.997
AA 0 0 A 0.003
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for the APOAI rs670 polymorphism with carriers of the
A allele (n = 185) displaying higher LDL-C levels than
individuals with the homozygote GG genotype (n = 344)
(Table 3). An association (p = 0.03) was also found be-
tween the APOAI rs670 polymorphism and TC levels
with carriers of the A allele (n = 191) displaying higher
TC levels than individuals with homozygous GG genotype
(n = 358) (Table 3). Neither HDL nor TG were signifi-
cantly associated (p > 0.05). In a multivariate analysis
using logistic regression the APOAI rs670 was found to
be an independent predictive factor when controlling
for age, sex and BMI for both TC and LDL-C levels
with an odds ratio of 1.77 (95% CI: 1.17-2.69, p = 0.006)
and 1.66 (95% CI: 1.10-2.51 p = 0.014), respectively
(Table 4). No significant association was observed between
the genotypes of the APOAI rs5069 and rs1799837
polymorphisms with regards to all the parameters ana-
lyzed including serum lipid levels and family history of
dyslipidemia (data not shown).
Discussion
The present study is the first to report sequence analysis
of the APOAI promoter region in an Arab ethnic group
among the Kuwaiti population. Previous studies on the
association of APOAI polymorphisms and variation in
serum lipid levels have relied mainly on PCR-RFLP pro-
filing [11,16,20,24,29,31,35] while a few studies have
performed re-sequencing [13,19,42,43]. No novel sequences
were observed in the sampled Kuwaiti population nor
was the previously reported APOAI −27 polymorphism
[13] in a Japanese boy, suggesting this one to be ethnic
specific, not having been reported in many other popula-
tions. The other reported SNPs (CR991531, HR971651,
rs12721302, rs372263101, rs199729971, rs141383703, rs3
68534370 and CS991294) in the target region sequenced
were not identified in any of the Kuwaiti samples probably
as a consequence of these SNPs being very rare (<0.01)
in a given population and could be ethnic specific. Inaddition, the absence of novel SNPs in the Kuwaiti
population, comprising mainly of Arab ethnicity, could
reflect the biological importance of conserving the pro-
moter region and the 5’ upstream sequence from the first
transcription site at the APOAI gene locus. This would
then ensure the integrity of its biological function in regu-
lating APOAI gene expression, effecting regulation of
gene expression of neighboring genes in the same cluster
on chromosome 11, or influencing the expression of other
apolipoprotein gene family. The integrity of the sequence
upstream of the transcription site has also been reported
to be essential to achieve sufficient expression of apoA-I
[42,44] as various mutations in the promoter region result
in marked reduction of APOAI expression and serum
protein levels [44]. Moreover, sequence analysis of the
promoter region has allowed identification of polymor-
phisms to be associated with extremely low concentrations
of HDL-C. Matsunaga et al. [13] showed that compound
heterozygosity of mutations at the promoter region
(−27 and −75) resulted in significantly reduced levels of
APOAI expression subsequently leading to reduced
levels of apoA-I and HDL-C. Henakhaus et al. [43] also
conducted sequence analysis of 94 South Asian immi-
grants in the USA and reported several polymorphisms
in the APOAI gene (1683 bp), including the APOAI
rs670. Specific hereditary patterns were common in this
ethnic group, and that their frequencies were different
from Europeans, suggesting the interaction of race and
ethnicity on APOAI gene expression. Haase et al. [19]
conducted a molecular analysis of the APOAI gene
locus in over 10000 Danish individuals and reported a
positive association between the APOAI −75 polymorph-
ism and LDL and TC levels, and that homozygosity of
APOAI rs670 A and heterozygosity of the APOAI rs5069
polymorphism were associated with increased HDL-C and
apoA-I levels. This is consistent with our observation that
the APOAI rs670 polymorphism is correlated with serum
TC and LDL-C. In many of the studies reviewed, carriers
of the minor A allele had significantly increased levels
of LDL when compared with homozygote individuals
with the wildtype G allele implicating it as a “risk” allele.
On the other hand, our analysis of the APOAI rs670
and rs5069 genotypes with variation in HDL-C levels
was in disagreement with Haase et al. [19] which may be
due to the limitation in our sample size and ethnic vari-
ation. Several studies [13,19,24,31,32,42,44] have reported
inconsistent results with regard to the effect of the APOAI
polymorphisms including rs670 on HDL-C levels and
its actual association with serum lipid levels. In compari-
son, Daneshpour et al. [29] documented an association
between APOAI haplotypes consisting of the A allele
with variation in serum TC and LDL-C levels. It has been
suggested that the A allele is not directly responsible for
the associative effect on serum APOAI and HDL-C levels










Figure 2 Mean lipid levels as function of two APOAI SNPs, rs670 (g.-75G > A) and the rs5069 (g. + 83C > T). Values shown are the
mean ± SEM. p values were estimated according to Kruskal-wallis ANOVA and are shown. The Mann–Whitney U test was used to compare wild
type genotypes against heterozygous and mutant genotypes combined, *, p < 0.05.
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through linkage disequilibrium to regulate apoA-I levels
[31] thereby affecting variation in serum HDL-C and TC
levels. This may very well explain the results obtained
in this study where carriers of the APOAI rs670 A allele
were 1.77 times more at “risk” of increased TC levels
(p = 0.006) and 1.66 times more likely to have increased
LDL-C (p = 0.014) than those with the GG genotypewhen controlling for age, sex and BMI in the Kuwaiti
population. The biological importance of APOAI rs670 is
in its creation of an inverted sequence repeat homologous
to other functional regulatory elements; such a mutation
could have an important effect on the regulation by tran-
scriptional factors [42] that may also affect other gene loci.
Furthermore, the positive association (60.2% power calcu-
lation estimate with a 5% significance) observed between
Table 3 Association of the APOAI rs670 (g.-75G > A) and the rs5069 (g. + 83C > T) polymorphisms and lipid profiles
SNP W/W W/M M/M p
n n n
SNPs relation with LDL
rs670 344 2.99 ± 0.04 164 3.17 ± 0.06 21 3.03 ± 0.14 0.02
rs5069 491 3.07 ± 0.03 37 3.02 ± 0.14 1 3.00 0.59
SNPs relation with TC
rs670 358 4.58 ± 0.04 170 4.75 ± 0.07 21 4.64 ± 0.19 0.03
rs5069 511 4.64 ± 0.04 37 4.60 ± 0.16 1 5.12 0.78
SNP relation with HDL
rs670 344 1.18 ± 0.01 164 1.15 ± 0.02 21 1.28 ± 0.1 0.22
rs5069 491 1.18 ± 0.01 37 1.15 ± 0.04 1 1.02 0.79
SNP relation with TG
rs670 358 0.74 170 0.72 21 0.68 0.93
(0.49–1.21) (0.48–1.14) (0.40–0.95)
rs5069 511 0.72 37 0.78 1 2.35 0.83
(0.48–1.18 (0.53–1.15)
W/W, homozygous for common allele; W/M heterozygous for minor allele; M/M, homozygous for minor allele. The lipid level values are represented as mmol/L.
Data shown as means ± SEM or for the lipid levels except for TG where the median and inter-quartile range is represented. p values were derived from multiple
linear regressions with adjustment for sex, BMI and age assuming an additive genetic model. Significant values (p < 0.05) are shown in bold.
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is more likely to be due to linkage disequilibrium with
other polymorphisms in candidate and neighboring genes
of lipid metabolism and/or transport such as APOB and
LCAT which could be ethnic specific. This may somehow
hinder the metabolism of LDL-C by the peripheral tissues
leading to the failure of cholesterol esters entering the
reverse cholesterol pathway and subsequently result in
increased serum TC and LDL levels. However, no signifi-
cant association was found with variation in lipid levels
in the Kuwaiti population as indicated by the univariateTable 4 Association of the APOAI rs670G > A genotype
with total cholesterol and LDL-C
Variable OR 95% CI P-value
A. Cholesterol grouped (High vs Normal)
APOA rs670 1.77 (1.17–2.69) 0.006
Age 1.02 (1.00–1.03) 0.002
Sex 1.12 (0.74–1.70) 0.579
BMI 1.05 (1.02–1.09) 0.0004
B. LDL grouped (Normal vs Abnormal)
APOA rs670 1.66 (1.10–2.51) 0.014
Age 1.02 (1.00–1.03) 0.003
Sex 1.77 (1.18–2.65) 0.005
BMI 1.05 (1.02–1.08) 0.0006
The values represented include the odds ratio, confidence interval and p
values as evaluated by multivariate analysis using logistic regression in 549
Kuwaiti individuals grouped based on their TC and LDL-C values according to
the population normal reference values. Multivariate analysis shows the APOAI
rs670 to be a significant (p < 0.05) independent predictive factor when
controlling for age, sex and BMI for both cholesterol and LDL levels.analyses which is in consistent with others who did not
observe an association between these changes that affect
the MspI restriction site polymorphisms on HDL-C levels
[32,45-49]. Wang et al. [16], however, reported a signifi-
cant association of HDL-C with two SNPs (rs5069 and
rs1799837) in which both were reported to be in link-
age disequilibrium. Inconsistent results especially for
the rs5069 and rs1799837 may sometimes arise from
genotyping errors by PCR-RFLP due possibly to their
adjacent positions as well as to several other factors. It
has been suggested that the majority of the RFLPs are due
to neutral mutations which probably do not directly affect
the structure of the mature protein or the regulation of its
neighboring genes [42]. This may also be the reason for
the limited number of studies analyzing the +84 poly-
morphism. Nonetheless, this study further supports the
designation of the APOAI rs1799837A allele as a “rare”
allele.
The Kuwaiti population is heterogeneous comprised
of a major Arab ethnic group including mostly bedouins, a
minor Iranian ethnic group and admixes of other ethnici-
ties [50]. Kuwait is a country that was first inhabited dur-
ing the early 18th century by Arab nomads and merchants
migrating from the Arabian Peninsula, Mesopotamia and
East Asia [50]. The origins of most of the current popula-
tion of more than one million can be traced to three
distinct regions now known as Saudi Arabia, Iran and
Iraq comprising mainly Arabs whose ancestors were from
the Arabian Peninsula and directly settled in Kuwait in the
19th century [50]. More recently, migrants from different
parts of Asia (e.g. Jordan, Lebanon, and Syria, India) and
Al-Bustan et al. BMC Medical Genetics 2013, 14:90 Page 8 of 11
http://www.biomedcentral.com/1471-2350/14/90North East Africa (e.g. Egypt and Greater Morocco) have
also settled in Kuwait leading to increased admixture be-
tween the different subpopulations. Based on the analysis
of the APOAI promoter region, the genetic contribution
from each ethnic group into the Kuwaiti general gene pool
is minimal that it doesn’t appear to have made much
difference in the distribution of the genotypes among
the different subpopulations (p > 0.05). Moreover, vari-
ation in lipid levels as a result of the contribution of
other Arab ethnic groups in the Kuwaiti population is
also minimal as the number of samples with such eth-
nicity is low (< 5%) therefore does not appear to have
affected the normal distribution of TC, HDL and LDL
levels. This makes it difficult to conduct analysis on the
genotypes of such ethnic groups and their association
to variation in HDL levels.
The genotype analysis of the three polymorphisms in
the studied Kuwaiti population and in the two major
ethnic groups showed the genotype and allele frequen-
cies to be in HWE suggesting any positive finding to be
more likely related to the biological function of the
APOAI rs670 than to population stratification. In addition,
the contribution made by the Kuwaiti-Iranian subpopula-
tion (22.77%) did not result in any significant difference
to the overall population genotype frequency distribu-
tion. The allele frequency distribution at the three loci
was compared to other reported populations (Table 5).
The allelic frequency in the Kuwaiti population was





Africans (Nigeria) 786 0.899
Caucasians 243 0.779
Europeans 1078 0.841
Europeans (Danish) 190* 0.810
10273 0.810
French Canadians 653 0.850
Brazilians 414
Chinese 1030 0.364
Hei Yi Zhaung Chinese 474 0.703
Han Chinese 564 0.660





*Based on re-sequencing of the APOAI promoter region [19].between the low 10% frequency reported for Africans
[17] and for Iranians (13.8%) [26] and the high 63.6% in
Chinese [11] while being approximately similar to those
of Omani Arabs, Caucasian and Europeans (15-22%)
[15,24,35] as well as being very close to the Danish
[19]. However, the observed +83T frequency (3.6%) is
lower to the range of 5.1-7.8% reported for Omanis and
Iranians (18,27) and much lower than that of the African
population (17) yet similar to the 3.5-4.0% reported in the
Europeans Danes (19). The reported frequencies suggest
demographic and gene flow patterns which need further
investigation. Li et al. [20] also reported that variation
in allelic frequencies at the APOAI rs670 between two
subpopulations in China and the rare allelic frequency
was different from Caucasians while being lower than
in other oriental races suggesting the utility of this SNP
in distinguishing various races. Those similar allelic fre-
quencies could be attributed to a common ancestor
homology. The inter-population sequence variation and
allelic frequencies in the APOAI promoter region could
variably modulate APOAI expression [16,19,22,23,32]
subsequently leading to effects on serum lipid levels that
manifest themselves in different ways in different popula-
tions. A GWA study conducted by the Global Lipids
Genetic Consortium [51] in Europeans did not report any
association of the three analyzed SNPs in the present
study with variation in lipid levels as they were not
covered by any of the microarray platforms used in the
analysis. However, the study reported an association9 allelic frequencies reported in this study with
SNP allele frequency Reference
rs5069
A C T
0.101 0.598 0.402 Kamboh et al. [17]
0.221 0.959 0.041 Wang et al. [16]
0.159 Talmud et al. [24]
0.190 0.965 .035 Haase et al. [19]
0.019 0.960 .040
0.150 Minnich et al. [31]
0.180 De Franca et al. [32]
0.636 - - Yin et al. [11]
0.298 - - Li et al. [20]
0.340 - - Li et al. [20]
0.311 0.949 0.051 Ma et al. [18]
0.156 0.922 0.078 Shioji et al. [27]
0.138 0.946 0.054 Daneshpour et al. [29]
0.217 0.933 0.067 Al-Yahyaee et al. [35]
0.193 0.964 0.036 Present study
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http://www.biomedcentral.com/1471-2350/14/90with SNP rs964184 [51]. To investigate if the two studied
SNPs (rs670 and rs5069) were in LD with the published
SNP, the Proxy SNPs rs11216153 and rs7123326 used
in the Hapmap and 1000genome data was used to tag
the two SNPs. The analysis showed that rs964184 was
not in LD with rs670 and rs5069 (r2 = 0.116 and r2 = 0.006
respectively). Likewise, the rs9326246 recently published
by the CardioGramplusC4D [52] cconsortium was tagged
by another Proxy SNP rs7350481 and was found not to
be in LD with rs11216153 and rs7123326 (r2 = 0.015
and r2 = 0.005 respectively).
Conclusion
In this study, three specific polymorphisms were geno-
typed by re-sequencing the APOAI promoter region
including the common rs670 polymorphism along with
the rare polymorphisms at the +83 and +84 loci in a
single reaction, overcoming problems with genotyping
errors frequently observed with PCR-RFLP. The present
study showed that the Kuwaiti population could be genet-
ically disposed to developing dyslipidemia in the presence
of the APOAI rs670 polymorphism and other SNPs which
need to be further investigated. Re-sequencing was
found to be a more informative option, especially if
inter-population variation and ethnicity have a role in
the genetic association of the gene and its outcomes.
With recent advances and the availability of high perform-
ance, cost effective automated gene analyzers such as
Next-Generation sequencing, conducting high throughput
genotyping and mutation screening of candidate genes in
lipid metabolism and/or transport is highly recommended
for different ethnic groups and in a larger sample size in
order to better understand the differences in population
frequencies, and to more accurately define “risk” and “pro-
tective” alleles from those which are simple variants. This
will assist in the goal towards personalized and preventive
medicine.
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